

PRESS RELEASE

06 November 2025 08:00:00 CET

Saniona AB's Nomination Committee for the Annual General Meeting 2026

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announces the composition of the Nomination Committee for the Annual General Meeting 2026

Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2025, the two largest shareholders, who desired to appoint representatives to the Nomination Committee, were Jørgen Drejer and Joakim Tedroff. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB's Nomination Committee for the Annual General Meeting 2026.

The Nomination Committee's members are:

- Joakim Tedroff, CMO at Irlab Therapeutics AB, appointed by Joakim Tedroff
- Søren Skjærbæk, Partner at Life Science Legal ApS, Vejle, Denmark, appointed by Jørgen Drejer
- John Haurum, Chairman of Saniona AB's Board

Søren Skjærbæk has been appointed as Chairman of the Nomination Committee.

The Nomination Committee shall prepare and submit proposals to the Annual General Meeting 2026 regarding:

- election of the Chairman at the Annual General Meeting;
- election of the Chairman and other members of the Board;
- remuneration for the Chairman and for each of the other members of the Board and, if applicable, remuneration for committee work;
- election of the auditor and the auditor's remuneration; and
- principles for appointing the Nomination Committee.

The instruction and charter for the Nomination Committee can be found in the Corporate Governance section at the company's website, www.saniona.com.

Saniona AB's Annual General Meeting will be held on Wednesday May 27, 2026, in Malmö. The Nomination Committee's proposals will be presented in the notice to the Annual General Meeting and on the company's website.

Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to clo@saniona.com marked "Recommendation to the Nomination Committee" or by ordinary mail to the address:

Saniona AB
Att: Recommendation to the Nomination Committee
Murervangen 42
DK-2600 Glostrup
Denmark

To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than February 28, 2026.

For more information, please contact

Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com

About Saniona

Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company's internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico and Argentina, where a market authorization application is currently under review. In addition, Saniona has two clinical-stage programs available for partnering: Tesomet™, ready to advance to Phase 2b trials in rare eating disorders, and SAN903, ready to enter Phase 1 trials in inflammatory bowel disease. Saniona's ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and CephaGenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

Attachments

Saniona AB's Nomination Committee for the Annual General Meeting 2026